유럽 연합 - 영어 - EMA (European Medicines Agency)

merck sharp dohme ltd - laropiprant, nicotinic acid - dyslipidemias - lipid modifying agents - pelzont is indicated for the treatment of dyslipidaemia, particularly in patients with combined mixed dyslipidaemia (characterised by elevated levels of low-density-lipoprotein (ldl) cholesterol and triglycerides and low high-density-lipoprotein (hdl)cholesterol) and in patients with primary hypercholesterolaemia (heterozygous familial and non-familial).pelzont should be used in patients in combination with 3-hydroxy-3-methylglutaryl-coenzyme-a (hmg-coa)-reductase inhibitors (statins), when the cholesterol lowering effect of hmg-coa-reductase inhibitor monotherapy is inadequate. it can be used as monotherapy only in patients in whom hmg-coa-reductase inhibitors are considered inappropriate or not tolerated. diet and other non-pharmacological treatments (e.g. exercise, weight reduction) should be continued during therapy with pelzont.

유럽 연합 - 영어 - EMA (European Medicines Agency)

merck sharp dohme ltd. - laropiprant, nicotinic acid - dyslipidemias - lipid modifying agents - tredaptive is indicated for the treatment of dyslipidaemia, particularly in patients with combined mixed dyslipidaemia (characterised by elevated levels of low-density-lipoprotein (ldl) cholesterol and triglycerides and low high-density-lipoprotein (hdl) cholesterol) and in patients with primary hypercholesterolaemia (heterozygous familial and non-familial).tredaptive should be used in patients in combination with 3-hydroxy-3-methyl-glutaryl-co-enzyme-a (hmg-coa)-reductase inhibitors (statins), when the cholesterol-lowering effect of hmg-coa-reductase inhibitor monotherapy is inadequate. it can be used as monotherapy only in patients in whom hmg-coa-reductase inhibitors are considered inappropriate or not tolerated. diet and other non-pharmacological treatments (e.g. exercise, weight reduction) should be continued during therapy with tredaptive.

유럽 연합 - 영어 - EMA (European Medicines Agency)

merck sharp dohme ltd - laropiprant, nicotinic acid - dyslipidemias - lipid modifying agents - trevaclyn is indicated for the treatment of dyslipidaemia, particularly in patients with combined mixed dyslipidaemia (characterised by elevated levels of low-density-lipoprotein (ldl) cholesterol and triglycerides and low high-density-lipoprotein (hdl) cholesterol) and in patients with primary hypercholesterolaemia (heterozygous familial and non-familial).trevaclyn should be used in patients in combination with 3-hydroxy-3-methyl-glutaryl-co-enzyme-a (hmg-coa)-reductase inhibitors (statins), when the cholesterol-lowering effect of hmg-coa-reductase-inhibitor monotherapy is inadequate. it can be used as monotherapy only in patients in whom hmg-coa-reductase inhibitors are considered inappropriate or not tolerated. diet and other non-pharmacological treatments (e.g. exercise, weight reduction) should be continued during therapy with trevaclyn.

뉴질랜드 - 영어 - Medsafe (Medicines Safety Authority)

merck sharp & dohme (new zealand) limited - laropiprant 20mg;  ; nicotinic acid 1000mg - tablet - active: laropiprant 20mg   nicotinic acid 1000mg excipient: colloidal silicon dioxide croscarmellose sodium hyprolose hypromellose lactose monohydrate magnesium stearate microcrystalline cellulose sodium stearyl fumarate

영국 - 영어 - MHRA (Medicines & Healthcare Products Regulatory Agency)

merck sharp & dohme ltd - laropiprant; nicotinic acid - modified-release tablet - 20mg ; 1gram

사우디아라비아 - 영어 - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

merck sharp & dohme - laropiprant, nicotinic acid - modified-release tablet - 1000, 20 mg

나미비아 - 영어 - Namibia Medicines Regulatory Council

msd (pty) ltd - niacin; laropiprant - tablet - each tablet contains 1 g extended -; release(er) niacin (nicotinic acid), immediate-release laropiprant 20,0 mg

싱가포르 - 영어 - HSA (Health Sciences Authority)

pfizer private limited - acipimox - capsule - 250 mg - acipimox 250 mg

싱가포르 - 영어 - HSA (Health Sciences Authority)

organon singapore pte. ltd. - simvastatin - tablet, film coated - 10.0 mg - simvastatin 10.0 mg

캐나다 - 영어 - Health Canada

qd pharmaceuticals ulc - simvastatin - tablet - 5mg - simvastatin 5mg - hmg-coa reductase inhibitors